Bevacizumab-FOLFOXIRI in First Line Treatment of BRAF V600E - Mutant Metastatic Colorectal Cancer: A Single-Center Study
Bevacizumab combined with mFOLFOXIRI is effective as first‑line therapy for metastatic colorectal cancer harboring the BRAF V600E mutation, achieving high objective response and disease control rates but accompanied by significant toxicities.
This study demonstrates that a combination of bevacizumab with triplet chemotherapy regimens can yield clinically meaningful response rates in a hard‑to‑treat population of BRAF V600E metastatic colorectal cancer patients, providing a potential first‑line treatment option while highlighting the need for careful toxicity management.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics